COMPASS Pathways

HMNC Brain Health to participate in CNS Summit 2024, presenting on precision psychiatry and psychedelics. Dr. Hans Eriksson will discuss psychedelics in mental health, while Dr. Daniel Gehrlach will present on precision psychiatry with genetic companion diagnostics.

COMPASS Pathways' Q3 2024 report shows increased operating expenses, net loss, and R&D tax credit. The company advances COMP360 psilocybin treatment for TRD with Phase 3 trials, expecting top-line data in 2025-2026. Financial challenges include significant R&D costs and need for additional funding.

DelveInsight's 'Bipolar Disorder (Manic Depression) Pipeline Insight, 2024' report details 22+ pipeline drugs from 22+ companies, segmented by RoA, MoA, and molecule types, with therapies in various clinical stages, including late-stage candidates like Vanda Pharmaceuticals' Iloperidone.

E.E.S. directs Instituto Phaneros and advises Reconnect Foundation; F.K. has received support from Tryp Therapeutics, holds stocks and consults for Cybin, holds stocks in Compass Pathways, and advises Apex Labs. Other authors declare no conflicts.

Ibogaine induces intense hallucinations, while tabernanthalog, a non-hallucinogenic analogue, offers altered states without trips. The definition of a trip is evolving as researchers develop non-hallucinogenic psychedelics for medical use, raising questions about what constitutes a psychedelic experience.

ADDF leads roundtable on combination therapy for Alzheimer’s at 2024 CTAD conference, highlighting the need for precision medicine and novel therapeutic targets beyond amyloid and tau.

The DEA proposed increasing psilocybin, psilocin, and ibogaine production quotas by 50% for 2025, signaling support for psychedelic research. This follows a growing interest in studying these compounds for mental health treatments, despite their Schedule 1 status. The VA is also increasingly involved in psychedelic-assisted therapy research for veterans.

Psychedelic drugs are nearing prescription for European patients with mental health issues, but hurdles remain. Research on psilocybin and MDMA is ongoing, with potential to treat conditions like depression and addiction. Controversy and challenges in study replication persist, but larger-scale studies and advances in brain scan technology are providing clearer insights. The first psychedelic to hit the European market may be from UK-based Compass Pathways, which is testing psilocybin for treatment-resistant depression. The psychedelic movement faces setbacks, such as US regulators rejecting MDMA for PTSD, which could delay access in Europe.

Compass Pathways to participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit on September 26, 2024, with a live audio webcast available on their website.